3-Chloro-N-cyclopropylcathinone (3Cl-CpC; code names PAL-433, RTI-6037-39) is a stimulant and hybrid monoamine releasing agent and monoamine reuptake inhibitor of the cathinone family related to bupropion (3-chloro-N-tert-butylcathinone). It acts specifically as a dual serotonin releasing agent (SRA) and serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI). Its EC50Tooltip half-maximal effective concentration for induction of serotonin release is 1,328 nM, whereas its IC50Tooltip half-maximal inhibitory concentration values for monoamine reuptake inhibition are 265 to 533 nM for dopamine, 2,150 nM for norepinephrine, and 3,180 nM for serotonin. The drug produces psychostimulant-like effects in animals, with a slow onset of action and a long duration of action. The activities of the individual enantiomers of 3Cl-CpC, (−)-3Cl-CpC (PAL-1122) and (+)-3Cl-CpC (PAL-1123), have also been reported. 3Cl-CpC was first described in the scientific literature by 2009. It was being investigated by the National Institute on Drug Abuse (NIDA) as a potential treatment of stimulant dependence, including cocaine dependence specifically.
See also 3-Chlorocathinone 3-Chloromethcathinone
References
External links 3Cl-CpC - Isomer Design